What You'll Want to Know About Sangamo Therapeutics' Q2 Results

Sangamo Therapeutics (NASDAQ: SGMO) keeps things interesting. Some investors might have been tempted to throw in the towel on the biotech stock earlier this year after Sangamo announced disappointing results from its phase 1/2 clinical study of SB-318 in treating rare genetic disease mucopolysaccharidosis type I (MPS I). But the biotech roared back several months later with positive results for experimental hemophilia drug SB-525.

The company reported its second-quarter results after the market closed on Wednesday. Here are the highlights from Sangamo's Q2 update.

Image source: Getty Images

Continue reading

Quelle Fool.com